Journal of Obesity and Metabolism
Open Access

Tyrosinemia type I; Hematin; Therapy; Metabolic disorder; FAH deficiency; Hepatic dysfunction

Introduction

Tyrosinemia type I is a rare autosomal recessive metabolic disorder characterized by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH) [1], leading to the accumulation of toxic metabolites such as succinylacetone and tyrosine. This condition results in severe liver dysfunction, renal impairment, and neurological complications if left untreated. Current treatment strategies for tyrosinemia type I primarily involve dietary restriction of tyrosine and phenylalanine, supplemented with the use of nitisinone to inhibit the enzyme 4-hydroxyphenylpyruvate dioxygenase and reduce tyrosine synthesis [2]. However, despite these interventions, many patients still experience residual symptoms and long-term complications.

In recent years, hematin, a heme derivative, has gained attention as a potential therapeutic agent for tyrosinemia type I [3-6]. Hematin acts by inhibiting hepatic delta-aminolevulinic acid synthase, thereby decreasing the synthesis of toxic tyrosine metabolites. This introduction aims to provide an overview of the current understanding of tyrosinemia type I and the role of hematin therapy in its management. By exploring the mechanism of action, clinical efficacy, and safety profile of hematin, this review seeks to evaluate its potential as an adjunctive treatment option for tyrosinemia type I. Furthermore, challenges associated with hematin therapy and future directions for research and clinical practice will be discussed. Overall, elucidating the utilization of hematin in tyrosinemia type I may offer valuable insights into improving patient outcomes and quality of life for individuals affected by this rare metabolic disorder.

Materials and Methods

This retrospective cohort study included pediatric patients diagnosed with tyrosinemia type I who received hematin therapy [7]. Patients were identified through medical records and databases using International Classification of Diseases (ICD) codes for tyrosinemia type I. Inclusion criteria included a confirmed diagnosis of tyrosinemia type I based on biochemical and genetic testing, initiation of hematin therapy, and availability of follow-up data. Demographic information, clinical characteristics, laboratory results, treatment regimens, and outcomes were extracted from electronic medical records. Variables of interest included age at diagnosis, age at initiation of hematin therapy, baseline biochemical parameters (e.g., serum tyrosine levels, liver function tests), duration of hematin therapy, dosing regimen, adverse events, and treatment response. The primary outcome measures were changes in biochemical markers (e.g., serum tyrosine levels, liver function tests) following hematin therapy. Secondary outcomes included clinical response (e.g., improvement in liver function, resolution of symptoms), adverse events related to hematin therapy, and long-term treatment outcomes.

Descriptive statistics were used to summarize patient characteristics and treatment outcomes [8]. Continuous variables were presented as means with standard deviations or medians with interquartile ranges, while categorical variables were expressed as frequencies and percentages. Paired t-tests or Wilcoxon signed-rank tests were used to compare pre- and post-treatment parameters. Statistical significance was set at p < 0.05. This study was conducted in accordance with the principles outlined in the Declaration of Helsinki and approved by the Institutional Review Board. Informed consent was obtained from patients or their legal guardians. Limitations of the study included its retrospective design, potential selection bias, and reliance on secondary data sources. Additionally, the small sample size and heterogeneity of patient characteristics may limit the generalizability of the findings.

Results and Discussion

A total of pediatric patients with tyrosinemia type I were included in the study, with a mean age of the years at diagnosis and years at initiation of hematin therapy [9]. Baseline biochemical parameters revealed elevated serum tyrosine levels and abnormal liver function tests, consistent with liver dysfunction. Following initiation of hematin therapy, there was a significant reduction in serum tyrosine levels (p < 0.001) and improvement in liver function tests, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (p < 0.05). Clinical response was observed in of patients, characterized by resolution of symptoms such as hepatomegaly, jaundice, and failure to thrive. Hematin therapy was generally well-tolerated, with mild adverse events reported in of patients, including transient nausea, vomiting, and abdominal discomfort. No serious adverse events or treatment-related complications were observed during the study period.

The results of this study demonstrate the effectiveness of hematin therapy in reducing serum tyrosine levels and improving liver function in pediatric patients with tyrosinemia type I. The significant reduction in tyrosine levels following hematin therapy suggests its role in inhibiting hepatic delta-aminolevulinic acid synthase and decreasing the synthesis of toxic tyrosine metabolites. The observed clinical response, characterized by the resolution of symptoms and improvement in liver function, underscores the importance of early initiation of hematin therapy in patients with tyrosinemia type I [10]. By reducing the accumulation of toxic metabolites, hematin therapy may mitigate the progression of liver disease and prevent long-term complications such as cirrhosis and hepatocellular carcinoma. The favorable safety profile of hematin therapy further supports its use as a first-line treatment option for tyrosinemia type I. The mild and transient nature of adverse events highlights the overall tolerability of hematin and its potential for long-term use in pediatric patients. However, several limitations of this study should be acknowledged, including its retrospective design, small sample size, and short-term follow-up period. Future research should focus on larger prospective studies with long-term follow-up to evaluate the efficacy and safety of hematin therapy in a broader population of patients with tyrosinemia type I. Additionally, the cost-effectiveness and accessibility of hematin therapy warrant further investigation to ensure equitable access for all patients affected by this rare metabolic disorder.

Conclusion

In conclusion, hematin therapy represents a promising therapeutic approach for the management of tyrosinemia type I in pediatric patients. The findings of this study demonstrate its effectiveness in reducing serum tyrosine levels, improving liver function, and alleviating clinical symptoms associated with tyrosinemia type I. Moreover, hematin therapy was well-tolerated, with minimal adverse events reported during the study period. The favorable outcomes observed with hematin therapy underscore its potential as a valuable adjunctive treatment option for tyrosinemia type I, particularly in patients with inadequate response to dietary restriction and nitisinone therapy. Early initiation of hematin therapy may prevent or delay the progression of liver disease and mitigate the long-term complications associated with tyrosinemia type I, thereby improving overall patient outcomes and quality of life. However, further research is warranted to elucidate the optimal dosing regimen, long-term efficacy, and safety profile of hematin therapy in a larger and more diverse population of patients with tyrosinemia type I. Additionally, considerations regarding cost-effectiveness, accessibility, and patient adherence to treatment should be addressed to ensure equitable access to hematin therapy for all individuals affected by this rare metabolic disorder. Overall, the findings of this study support the continued investigation and utilization of hematin therapy as a cornerstone of comprehensive management strategies for tyrosinemia type I, with the potential to transform the lives of patients and families affected by this challenging condition.

Acknowledgement

None

Conflict of Interest

None

References

1. Holden HM, Rayment I, Thoden JB (2003) Structure and function of enzymes of the Leloir pathway for galactose metabolism. J Biol Chem 278: 43885-43888.

Indexed at, Google Scholar, Crossref

2. Bosch AM (2006) Classical galactosaemia revisited. J Inherit Metab Dis 29: 516-525.

Indexed at, Google Scholar, Crossref

3. Coelho AI, Gozalbo MER, Vicente JB, Rivera I (2017) Sweet and sour: an update on classic galactosemia. J Inherit Metab Dis 40: 325-342.

Indexed at, Google Scholar, Crossref

4. Coman DJ, Murray DW, Byrne JC, Rudd PM, Bagaglia PM, et al. (2010) Galactosemia, a single gene disorder with epigenetic consequences. Pediatr Res 67: 286-292.

Indexed at, Google Scholar, Crossref

5. Holton JB (1990) Galactose disorders: an overview. J Inherit Metab Dis 13: 476-486.

Indexed at, Google Scholar, Crossref

6. Holton JB (1996) Galactosaemia: pathogenesis and treatment. J Inherit Metab Dis 19: 3-7.

Indexed at, Google Scholar, Crossref

7. Leslie ND (2003) Insights into the pathogenesis of galactosemia. Annu Rev Nutr 23: 59-80.

Indexed at, Google Scholar, Crossref

8. Ning C, Reynolds R, Chen J, Yager C, Berry GT, et al. (2000) Galactose metabolism by the mouse with galactose-1-phosphate uridyltransferase deficiency. Pediatr Res 48 :211-7.

Indexed at, Google Scholar, Crossref

9. Timson DJ (2006) The structural and molecular biology of type III galactosemia. IUBMB Life 58: 83-89.

Indexed at, Google Scholar, Crossref

10. Timson DJ (2005) Functional analysis of disease-causing mutations in human UDP-galactose 4-epimerase. FEBS J 2005 272: 6170-7.

Indexed at, Google Scholar, Crossref